Imran Khan
PDF VETERAN
- Joined
- Oct 18, 2007
- Messages
- 68,815
- Reaction score
- 5
- Country
- Location
any data for confirmation ?Just deaths from ineffectiveness
threatened into taking his statement back.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
any data for confirmation ?Just deaths from ineffectiveness
threatened into taking his statement back.
any data for confirmation ?
any data for confirmation ?
The problem with the coversation you are having with the poster is 2 fold:
1. Will want to "big-up" China as China is Pakistan's most important ally.
2. Pakistan has brought a whole load of the same Chinese vaccines.
Saying that nearly 60% efficacy after 2 doses is not bad for the Chinese but the problem is that vaccines from US and Europe are in the mid-90s.
It is not a tech thing per se as AstraZeneca is not mRNA based and also gives the mid-90s effectiveness from hospitalisation as both the Pfizer and Moderna vaccines, although only around 70-80% effective from symptomatic infections.
Canada is losing the race between vaccines and variants as the 3rd wave worsens
https://www.cbc.ca/news/health/coronavirus-variants-canada-covid-19-vaccine-third-wave-1.5978394 Variants rapidly outpacing vaccinations as third wave shows no signs of slowing down Much of Canada is in the grips of a worsening third wave as COVID-19 vaccinations slowly ramp up, and experts...defence.pk
Big problem the guy dbc lacks is, that look at the number of cases and deaths in UK, USA, Europe now, it is 100 times more than China, Pakistan, Mideastern states, these western countries where Pfizer, AstraZeneca and Moderna vaccines are only given to and the effect on different variants is too less.
The problem with the coversation you are having with the poster is 2 fold:
1. Will want to "big-up" China as China is Pakistan's most important ally.
2. Pakistan has brought a whole load of the same Chinese vaccines.
Saying that nearly 60% efficacy after 2 doses is not bad for the Chinese but the problem is that vaccines from US and Europe are in the mid-90s.
It is not a tech thing per se as AstraZeneca is not mRNA based and also gives the mid-90s effectiveness from hospitalisation as both the Pfizer and Moderna vaccines, although only around 70-80% effective from symptomatic infections.
“So from the Brazilian slides on this Sinovac vaccine trial, it appears that the numbers of infected/symptomatic COVID-19 cases in the trial were stratified into mild (85 in the vaccine arm vs. 167 in the placebo arm), moderate (7 vs. 31), and severe (0 vs. 7).
“With vaccine efficacies calculated as 1 – relative risk (RR) of the vaccine (Sinovac) being able to prevent mild (50%), moderate (78%), and severe (100%) symptomatic COVID-19 cases.
“The mild, moderate, severe disease end-points used here may differ slightly from the other vaccine trials but the overall range of efficacy values for the mild/moderate/severe COVID-19 endpoints may actually not differ that much from the Oxford-AstraZeneca vaccine efficacy range of 60-90%, with their low and standard dose formulations.”
Are you sure you are not mixing up reports?Big problem the guy dbc lacks is, that look at the number of cases and deaths in UK, USA, Europe now, it is 100 times more than China, Pakistan, Mideastern states, these western countries where Pfizer, AstraZeneca and Moderna vaccines are only given to and the effect on different variants is too less.
“The reporting of the Sinovac trial of Coronavac (an inactivated whole virus vaccine) is very confusing. The revised 50.4% efficacy rate from the Brazilian clinical trial includes those who had ‘very mild’ cases of COVID-19 whereas original reports indicated an overall efficacy of 78% for mild to severe cases. The same vaccine has been trialled in Turkey (reported efficacy 91.25%) and Indonesia (reported efficacy 65.3%).
The latest figures for China's coronavirus vaccine show just how difficult it is to compare vaccines.
On the face of it, the 50% effectiveness figure isn't as good as Oxford's 70% or Pfizer and Moderna's 95%. But trials are run very differently in different countries - the numbers of volunteers enrolled varies wildly, as do the criteria used to test how much protection the vaccines offer.
A figure for efficacy is reached by looking at how many people developed Covid after being given the vaccine, compared with how many were affected when given a dummy injection. Normally, that is based on people developing obvious symptoms but in this Brazilian trial, people with no symptoms also appear to have been included.
Big problem the guy dbc lacks is, that look at the number of cases and deaths in UK, USA, Europe now, it is 100 times more than China, Pakistan, Mideastern states, these western countries where Pfizer, AstraZeneca and Moderna vaccines are only given to and the effect on different variants is too less.
I think there needs to start being lawsuits filed against slanderous news organizations. it is clear that they have not only spread fake news but do so with the intent of causing grevious financial harm and obstructing critical medical supply distribution.
I completely agree, the Global times for example ran a series of articles back in January attcking the Pfizer vaccine with false allegations linking it to deaths in Norway.